{"id":"W3213621180","doi":"10.1182/blood-2021-153315","title":"DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Tolerability; Cohort; Bortezomib; Regimen; Internal medicine; Oncology; Adverse effect; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00209589,0.001197269,0.001873672,0.0004278788,0.0004098977,0.001200192,0.001408449,0.0009753779,0.003579292],"category_scores_gemma":[0.001125637,0.0006713035,0.00168748,0.0004033973,0.0008610376,0.001064096,0.0005940514,0.004247163,0.0009687117],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001727205,"about_ca_system_score_gemma":0.002247954,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001517368,"about_ca_topic_score_gemma":0.004020914,"domain_scores_codex":[0.9994153,0.0002653264,0.0000405141,0.0001149203,0.00006409929,0.00009984005],"domain_scores_gemma":[0.9991181,0.0001165184,0.00018438,0.00007087037,0.00005345394,0.0004565732],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6799935,0.1422689,0.0099913,0.001594804,0.002150949,0.0002516081,0.0004543584,0.003200497,0.03288167,0.0004372302,0.004887553,0.1218876],"study_design_scores_gemma":[0.4802042,0.5049595,0.00850885,0.00004709729,0.0003827794,0.0002651754,0.00006629133,0.00105031,0.001930249,0.0001538667,0.002401061,0.00003068396],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892088,0.003127686,0.0006648101,0.0005561113,0.0001952358,0.002653516,0.001371796,0.0001532197,0.002068793],"genre_scores_gemma":[0.9883766,0.001635417,0.002658091,0.0008644717,0.0001456401,0.002290631,0.002050546,0.00002474575,0.001954034],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003579292,"threshold_uncertainty_score":0.01253182,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01204093776125405,"score_gpt":0.2802904466225992,"score_spread":0.2682495088613452,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}